

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NEW YORK

IN RE: ORAL PHENYLEPHRINE
MARKETING AND SALES PRACTICES
LITIGATION

THIS DOCUMENT APPLIES TO:

Coyle v. GlaxoSmithKline LLC, et al, No. 1:23-cv-07311-BMC (E.D.N.Y.)

Butler v. Johnson & Johnson – New Jersey, et al, No. 2:23-cv-07497-BMC (E.D.N.Y.)

Pack, et al. v. Johnson & Johnson Consumer Companies, Inc., et al, No. 1:23-cv-09057-BMC (E.D.N.Y.)

Juneau v. The Procter & Gamble Company, et al, No. 1:23-cv-09060-BMC (E.D.N.Y.)

Barton, et al v. RB Health (US) Inc., et al, No. 1:23-cv-09063-BMC (E.D.N.Y.)

Nelson, et al v. Johnson & Johnson, Inc., et al, No. 1:23-cv-09261-BMC (E.D.N.Y.)

McPhee, et al. v Johnson & Johnson Consumer Companies, Inc., et al, No. 1:23-cv-09262-BMC (E.D.N.Y.)

Valdes v. McNeil Healthcare, et al, 1:23-cv-09267-BMC (E.D.N.Y.)

Silva v. Reckitt Benckiser LLC, et al, No. 1:23-cv-09268-BMC (E.D.N.Y.)

De Priest, et al v. Walgreen Co., et al, No. 1:23-cv-09272-BMC (E.D.N.Y.)

Hsieh, et al v. RB Health (US) LLC, et al, No. 1:23-cv-09274-BMC (E.D.N.Y.)

Means v. Johnson & Johnson Consumer Inc., et al, No. 1:23-cv-09276-BMC (E.D.N.Y.)

Fong v. Johnson & Johnson Consumer Inc., et al, No. 1:23-cv-09278-BMC (E.D.N.Y.)

Murdock, et al v. RB Health (US) LLC, et al, No. 1:23-cv-09279-BMC (E.D.N.Y.)

Case No. 1:23-MD-03089-BMC

NOTICE OF APPEARANCE OF ROBYN E. BLADOW

Heaghney v. Johnson & Johnson Consumer Inc., et al., No. 1:23-cv-09282-BMC (E.D.N.Y.)

Adkins, et al v. Reckitt Benckiser Pharmaceuticals Inc., et al, No. 1:23-cv-09291-BMC (E.D.N.Y.)

Wilson v. Johnson & Johnson Consumer, Inc., et al, No. 1:23-cv-09296-BMC (E.D.N.Y.)

Jones v. Bayer Corporation, et al, No. 1:23-cv-09297-BMC (E.D.N.Y.)

Rourk v. Haleon, Plc, No. 1:23-cv-09298-BMC (E.D.N.Y.)

Chavez v. Johnson & Johnson Consumer Inc., et al., No. 1:23-cv-09304-BMC (E.D.N.Y.)

Travis v. Procter & Gamble Company, et al, No. 1:23-cv-09306-BMC (E.D.N.Y.)

Newton's Pharmacy, Inc. v. Procter & Gamble Company, et al, No. 1:23-cv-09307-BMC (E.D.N.Y.)

Parker v. Bayer Healthcare, LLC, et al, No. 1:23-cv-09311-BMC (E.D.N.Y.)

Kasparie, et al v. Bayer Healthcare, LLC, et al, No. 1:23-cv-09312-BMC (E.D.N.Y.)

Benjamin, et al v. GlaxoSmithKline LLC, et al, No. 1:23-cv-09313-BMC (E.D.N.Y.)

Anderson, et al v. The Procter & Gamble Company, et al, No. 1:23-cv-09315-BMC (E.D.N.Y.)

Chamberlain v. Johnson & Johnson Consumer Inc., et al, No. 1:23-cv-09316-BMC (E.D.N.Y.)

PLEASE TAKE NOTICE that the undersigned counsel, Robyn E. Bladow¹, of Kirkland & Ellis LLP, is admitted to practice *pro hac vice* in this Court and has no disciplinary matters pending, and hereby enters her appearance in the above-captioned cases as counsel for defendant

¹ On February 13, 2024, Robyn E. Bladow was granted *pro hac vice* admission in the action, In Re: Oral Phenylephrine Marketing and Sales Practices Litigation, 23-md-03089-BMC and individual related actions.

Haleon US Holdings LLC² (incorrectly named in some cases as GlaxoSmithKline Consumer Healthcare, Inc., GlaxoSmithKline LLC, GSK Consumer Health, Inc., GSK Consumer Healthcare, Inc., Haleon US Capital LLC, and Pfizer Inc.), as well as the above-referenced MDL Proceeding (MDL No. 3089), and respectfully requests that copies of all papers and electronic notices in this action be served upon her at the email address below.

Dated: February 16, 2024

Respectfully submitted,

/s/ Robyn E. Bladow
Robyn E. Bladow
KIRKLAND & ELLIS LLP
555 S. Flower Street
Los Angeles, CA 90071
Tel: (213) 680-8400
robyn.bladow@kirkland.com

Counsel for Haleon US Holdings LLC

² Effective December 8, 2023, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC changed its name to Haleon US Holdings LLC. This notice also identifies actions in which foreign entities GSK plc and Haleon plc have been named as defendants, although these entities are not properly served nor subject to jurisdiction in U.S. courts. By listing any matter herein, no party waives any jurisdictional defense or proper service of process.

CERTIFICATE OF SERVICE

I, Robyn E. Bladow, counsel for Defendant Haleon US Holdings LLC, hereby certify that on February 16, 2024, I electronically filed the foregoing documents with the Clerk of the Court using the CM/ECF system which will send notification of such filing to all attorneys of record. I further will cause the foregoing filed documents to be served via FedEx to the following:

Butler v. Johnson & Johnson et al., No. 2:23-cv-07497

Pro Se Plaintiff

Timothy Butler
Inmate No. 309172
Yaphank Correctional Facility
110 Center Drive South
Riverhead, NY 11901

By: /s/ Robyn E. Bladow
Robyn E. Bladow